B6.OT-II T cell receptor (TCR) transgenic mice and WT C57BL/6 or BALB/cJ mice were purchased from the Jackson Laboratories. IL-17RC–deficient mice were obtained from W. Ouyang (Genentech, San Francisco, CA) and were described previously (2). All animal experiments were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.